New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Reg... ( Data from EVEREST Patient Registry P...)

New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Regurgitation

Date:10/24/2007

Data from EVEREST Patient Registry Presented at TCT 2007; EVEREST II Study

Enrollment Continues

WASHINGTON, Oct. 24 /PRNewswire/ -- The vast majority of patients who had a successful result with the percutaneous MitraClip device did not need mitral valve surgery three years after their procedure, and many benefited from significantly improved function of the left ventricle (commonly known as reverse remodeling), according to data presented this week at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) symposium in Washington, D.C.

During multiple sessions at TCT 2007, researchers participating in the EVEREST II study presented data from a 107-person, non-randomized patient registry. The presentations evaluated the reduction of mitral regurgitation severity with the MitraClip device and the positive impact of this reduction for patients. The ongoing randomized study arm of EVEREST II is evaluating the safety and efficacy of the MitraClip device compared to surgical mitral valve repair or replacement for the treatment of mitral regurgitation (MR; a condition in which blood leaks backward through the mitral valve with each heartbeat, causing the heart to work harder to circulate oxygen to the body). Highlights of the data presented this week include:

36 Month Follow-up Shows Ongoing Effectiveness and Durability

-- 82 percent of patients who had a successful result with the MitraClip

device remain free from surgery 36 months after the procedure.

Reduction in Mitral Regurgitation Severity

-- 74 percent of patients with one or more Clips implanted experienced a

reduction to less than or equal to Grade 2+ MR as assessed by the

EVEREST Core Laboratory and graded per the American Society of

Echocardiography guidelines.

Significant Reverse Remodeling of the Left Ventricle

-- 12 months after a s
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging

Post Your Comments:

New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Reg...( Data from EVEREST Patient Registry P...),Health